XM does not provide services to residents of the United States of America.

Granules India Q2 profit falls on weak demand in North America, Europe



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Granules India Q2 profit falls on weak demand in North America, Europe</title></head><body>

Nov 6 (Reuters) -Drugmaker Granules India GRAN.NS reported a 4.8% fall in its second-quarter profit on Wednesday, dragged by a slow demand in the North American and European markets.

Consolidated profit fell to 972.3 million rupees ($11.54 million) for the quarter ended Sept. 30, from 1.02 billion rupees a year earlier.

Granules, which generates 66% of its revenue from North America and 19% from Europe, posted an 18.7% fall in its revenue from operations.

For further earnings highlights, (click here)




KEY CONTEXT

The company said its quarterly sales were impacted by a voluntary pause in manufacturing and distribution from its Gagillapur facility near Hyderabad, which deals with finished dosage and pharmaceutical formulations, due to an inspection by the U.S. Food and Drug Administration.

The drugmaker's revenue fell due to weak sales and price cuts from competition, despite expectations that Indian active pharmaceutical ingredient, or API, makers such as Granules would benefit from a rising demand in Europe and the U.S.




PEER COMPARISON






Valuation (next 12 months)

Estimates (next 12 months)

Analysts' sentiment



RIC

PE

EV/EBITDA

Price/Sales

Revenue growth (%)

Profit growth (%)

Mean rating*

# of analysts

Stock to price target**

Div yield (%)

Granules India

GRAN.NS

19.49

11.50

-

14.87

36.32

Strong Buy

3

0.85

0.27

Glenmark Life Sciences

GLEM.NS

23.44

15.72

-

11.92

12.61

Buy

6

0.98

2.12

Laurus Labs

LAUL.NS

56.43

22.49

-

13.87

86.09

Hold

11

1.18

0.16

Divi's Laboratories

DIVI.NS

65.63

46.64

15.77

15.93

26.45

Hold

23

1.29

0.52




* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT


JULY-SEPTEMBER STOCK PERFORMANCE

**

**

-- All data from LSEG

-- $1 = 84.2475 Indian rupees




Reporting by Yagnoseni Das in Bengaluru; Editing by Rashmi Aich

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.